The established dogma for meningococcus is thus that immunisation againstserogroups A, C, W135 and Y shall be based on the four different capsularsaccharides, and that immunisation against serogroup B shall not be based onthe capsular saccharide. In contrast, the invention uses polypeptide antigensand/or OMVs to immunise against serogroups A, C, W135 and Y (and againstserogroup Y in particular). Serogroup B polypeptides can achieve thisprotection, thus permitting a single polypeptide-based vaccine to be used forprotecting against all of serogroups A, B, C, W 135 and Y.
